A naturally occurring psychoactive alkaloid derived from the Iboga shrub being developed for addiction and neuro-regeneration.
2 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Ibogaine in the last 30 days yet.
The 2 sources with the most insights about Ibogaine on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
High-potency, high-reward biotech asset gaining bipartisan political support and institutional validation from Stanford, though currently a Schedule I substance with cardiac risks.
Clinical trials show an 85-98% success rate in clearing opioid addiction and significant neuro-regenerative capacity for PTSD and TBI.
High-potency, high-reward biotech asset gaining bipartisan political support and institutional validation from Stanford, though currently a Schedule I substance with cardiac risks.
Clinical trials show an 85-98% success rate in clearing opioid addiction and significant neuro-regenerative capacity for PTSD and TBI.
Other assets that creators frequently mention in the same content as Ibogaine.
The most active sources covering Ibogaine (IBOG) on Kazuha are The New York Times, Joe Rogan. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Ibogaine (IBOG) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Ibogaine (IBOG) most frequently also discuss KETM, DMT, MDMA, PSIL. See the "Discussed alongside" section above for full asset pages.